The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as critical to Biohaven’s future.
Biohaven stock slides on withdrawal of European marketing application
HOT NEWS
Techjockey Crosses 3,000 Software Brands as UAE Operations Complete First Year
UNITED ARAB EMIRATES — (ARAB NEWSWIRE) — Techjockey, a leading B2B software discovery and procurement…
تُظهر الدراسة أن وجبة الإفطار الغنية بالجوز من الممكن أن تساعد في تعزيز قوة دماغك
California Walnut كما أظهر بحثٌ جديد أن تناول الجوز في وجبة الإفطار يمكن أن يحسّن…
Arab Newswire Provides Press Release Distribution in Arabic
Arab Newswire - Press release distribution to media in MENA/GCC Regions Newswire expands reach with…